These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 15328077

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
    Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C.
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3801-8. PubMed ID: 16940065
    [Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
    Brendel K, Legrand M, Taburet AM, Baron G, Goujard C, Mentré F, Cophar 1-ANRS 102 Trial Group.
    Fundam Clin Pharmacol; 2005 Jun; 19(3):373-83. PubMed ID: 15910662
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
    Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T.
    Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
    Kappelhoff BS, Huitema AD, Sankatsing SU, Meenhorst PL, Van Gorp EC, Mulder JW, Prins JM, Beijnen JH.
    Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
    Curras V, Hocht C, Mangano A, Niselman V, Mariño Hernández E, Cáceres Guido P, Mecikovsky D, Bellusci C, Bologna R, Sen L, Rubio MC, Bramuglia GF.
    Pharmacology; 2009 Sep; 83(1):59-66. PubMed ID: 19052483
    [Abstract] [Full Text] [Related]

  • 9. Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.
    Cressey TR, Urien S, Hirt D, Halue G, Techapornroong M, Bowonwatanuwong C, Leenasirimakul P, Treluyer JM, Jourdain G, Lallemant M, PHPT-3 Team.
    Ther Drug Monit; 2011 Feb; 33(1):25-31. PubMed ID: 21233689
    [Abstract] [Full Text] [Related]

  • 10. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE, Wasmuth JC, Fätkenheuer G, Schneider K, Schmitz K, de Boo TM, Reiss P, Hekster YA, Burger DM, Rockstroh JK.
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [Abstract] [Full Text] [Related]

  • 11. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
    Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
    Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, Sangkote J, Bunyaprawit P, Horsakulchai M, Lange J, Cooper D, Phanuphak P, Ruxrungtham K.
    Antivir Ther; 2005 Jun; 10(2):301-7. PubMed ID: 15865224
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
    Colombo S, Buclin T, Décosterd LA, Telenti A, Furrer H, Lee BL, Biollaz J, Eap CB, Swiss HIV Cohort Study.
    Clin Pharmacol Ther; 2006 Oct; 80(4):307-18. PubMed ID: 17015049
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.
    Justesen US, Andersen AB, Klitgaard NA, Brøsen K, Gerstoft J, Pedersen C.
    Clin Infect Dis; 2004 Feb 01; 38(3):426-9. PubMed ID: 14727216
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study.
    Avihingsanon A, van der Lugt J, Singphore U, Gorowara M, Boyd M, Ananworanich J, Phanuphak P, Burger D, Ruxrungtham K.
    AIDS Res Hum Retroviruses; 2012 Oct 01; 28(10):1170-6. PubMed ID: 22250979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.